|
2026
|
P/S
|
Chemical ingredients; active chemical and biological ingredients for use in the manufacture of ph... |
|
|
P/S
|
Vaccines; vaccines for human use; flu vaccines Providing clinical trial research information abou... |
|
|
P/S
|
Vaccines; vaccines for human use; flu vaccines Scientific research in the nature of conducting cl... |
|
|
P/S
|
Active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely,... |
|
|
P/S
|
Vaccines |
|
|
P/S
|
Providing clinical trial research information about the results of clinical trials for flu vaccin... |
|
|
P/S
|
Vaccines. |
|
|
P/S
|
Vaccines. |
|
|
P/S
|
Providing educational information and medical information about immunology, Primary Immunodeficie... |
|
2025
|
Invention
|
Ionizable cationic compound. Novel ionizable lipid compounds of Formula I are provided. The use o... |
|
|
Invention
|
Potency assay. The present disclosure relates to methods for determining potency of multivalent R... |
|
|
Invention
|
Potency assay. The present disclosure provides a method for quantifying a target protein in a sam... |
|
|
Invention
|
Methods and reagents for treating or preventing ebv. The present disclosure relates to Epstein-Ba... |
|
|
Invention
|
Culture methods for virally-infected cells. The present disclosure relates to the field of method... |
|
|
Invention
|
Alternative self-amplifying rna. The present disclosure provides a self-amplifying RNA (sa-mRNA) ... |
|
|
Invention
|
Influenza vaccines. The present disclosure provides a RNA comprising a nucleotide sequence encodi... |
|
2024
|
Invention
|
Recombinant virus-like particles |
|
|
Invention
|
Combination rna vaccine |
|
|
Invention
|
Recombinant virus-like particles. The present disclosure relates to a recombinant virus-like part... |
|
|
Invention
|
In vitro transcription method. The present disclosure relates generally to methods of producing R... |
|
|
Invention
|
Combination rna vaccine. The present disclosure relates to combination RNA vaccines and uses ther... |
|
|
Invention
|
Sars-cov-2 rna vaccines and uses thereof |
|
|
Invention
|
Sars-cov-2 rna vaccines and uses thereof. The present disclosure relates to SARS-CoV-2 RNA vaccin... |
|
|
Invention
|
Improved seed viruses |
|
|
Invention
|
Improved seed viruses. The present disclosure relates to the field of influenza viruses. More par... |
|
|
Invention
|
Multivalent subtype influenza vaccine. The present disclosure relates to multivalent subtype infl... |
|
|
Invention
|
Virus-like particles for the treatment of sars-cov2 |
|
|
Invention
|
Virus-like particles for the treatment of sars-cov2. The present disclosure relates to a virus-li... |
|
|
Invention
|
Vaccine adjuvants |
|
|
Invention
|
Vaccine adjuvants. The present disclosure relates to RNAs and other polynucleotides encoding an a... |
|
|
Invention
|
Combination vaccine |
|
|
Invention
|
Combination vaccine. The present disclosure relates to compositions comprising multiple antigens ... |
|
|
Invention
|
Vaccine compositions |
|
|
Invention
|
Vaccine compositions. The present disclosure relates to RNAs and other polynucleotides encoding a... |
|
|
Invention
|
Rna delivery vehicle. The present disclosure relates to an RNA delivery vehicle comprising lipid ... |
|
|
P/S
|
Vaccines for human use. |
|
|
Invention
|
Ionizable cationic compound. Novel ionizable lipid compounds of Formula I-Het, Formula I and Form... |
|
|
Invention
|
Ionizable cationic compound |
|
|
Invention
|
Capping assay. The present disclosure relates to methods for quantifying mRNA capping efficiency.... |
|
2023
|
Invention
|
Lipid nanoparticle composition.
The present disclosure provides lipid nanoparticles having a sph... |
|
|
Invention
|
Lipid nanoparticle composition.
The present disclosure relates to compositions of RNA encapsulat... |
|
|
Invention
|
Lipid nanoparticle composition. The present disclosure provides lipid nanoparticles having a sphe... |
|
|
Invention
|
Lipid nanoparticle composition. The present disclosure relates compositions of RNA encapsulated i... |
|
|
Invention
|
Stabilized vaccines. The present disclosure relates to a fusion protein comprising an ectodomain ... |
|
|
Invention
|
Stabilized vaccines |
|
|
P/S
|
Pharmaceutical preparations for human use; vaccines. |
|
|
P/S
|
Pharmaceutical preparations and substances for human use for the treatment and prevention of vira... |
|
|
Invention
|
Lipid nanoparticle comprising a dna-binding protein. The present disclosure relates to lipid nano... |
|
|
Invention
|
Modified influenza viruses.
The present disclosure relates to the field of modified viruses and ... |
|
|
Invention
|
Modified influenza viruses |
|
|
Invention
|
Modified influenza viruses. The present disclosure relates to the field of modified viruses and v... |
|
|
Invention
|
Rna encoding virus-like particles and uses thereof.
The present disclosure relates to a composit... |
|
|
Invention
|
Vaccine for preventing or treating coronavirus infection.
The present specification relates to v... |
|
|
Invention
|
Mrna vaccine.
The present specification relates to vaccines comprising an mRNA polynucleotide en... |
|
2022
|
Invention
|
Ionizable cationic compound.
Novel ionizable lipid compounds of Formula I are provided. The use ... |
|
|
Invention
|
Ionizable cationic lipid for messenger rna delivery.
The use of an ionizable cationic lipid in f... |
|
|
Invention
|
Lipid nanoparticle comprising a nucleic acid-binding protein.
The present disclosure relates to ... |
|
|
Invention
|
Ionizable cationic compound.
Novel ionizable lipid compounds of Formula I or Formula II are prov... |
|
|
Invention
|
Ionizable cationic compounds for messenger rna delivery.
The use of certain ionizable cationic l... |
